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Strengths and limitations of this study
 ► This is the first randomised controlled trial on the 
use of a smartphone-delivered wound assessment 
tool to facilitate the assessment of surgical site in-
fection and the impact on time-to-diagnosis.
 ► There are broad eligibility criteria, and so it is expect-
ed the results will be generalisable to a wide popula-
tion of patients undergoing abdominal surgery.
 ► Due to the nature of the intervention, only clinicians 
undertaking follow-up can be blinded to randomis-
ation status.
 ► All patients will receive 30-day telephone or face-to-
face follow-up to determine the occurrence of sur-
gical site infections; however, the gold-standard for 
diagnosis remains direct clinical assessment.
 ► Data on patient experience and acceptability of 
smartphone-delivered follow-up will be collected 
concurrently to guide future implementation of fu-
ture telehealth interventions.
AbStrACt
Introduction National data suggest that surgical site 
infection (SSI) complicates 2%–10% of general surgery 
cases, although the patient-reported incidence is much 
higher. SSIs cause significant patient morbidity and 
represent a significant burden on acute healthcare 
services, in a cohort predominantly suitable for outpatient 
management. Over three-quarters of UK adults now own 
smartphones, which could be harnessed to improve access 
to care. We aim to investigate if a smartphone-delivered 
wound assessment tool results in earlier treatment.
Methods and analysis This is a randomised controlled 
trial aiming to recruit 500 patients across National Health 
Service (NHS) hospitals. All emergency abdominal surgery 
patients over the age of 16 who own smartphones 
will be considered eligible, with the exclusion of those 
with significant visual impairment. Participants will be 
randomised in a 1:1 ratio between standard postoperative 
care and the intervention – use of the smartphone tool in 
addition to standard postoperative care. The main outcome 
measure will be time-to-diagnosis of SSI with secondary 
outcome measures considering use of emergency 
department and general practitioner services and patient 
experience. Follow-up will be conducted by clinicians 
blinded to group allocation. Analysis of time-to-diagnosis 
will be by comparison of means using an independent two 
sample t-test.
Ethics and dissemination This is the first randomised 
controlled trial on the use of a smartphone-delivered 
wound assessment tool to facilitate the assessment of SSI 
and the impact on time-to-diagnosis. The intervention is 
being used in addition to standard postoperative care. The 
study design and protocol were reviewed and approved 
by Southeast Scotland Research and Ethics Committee 
(REC Ref: 16/SS/0072 24/05/2016). Study findings will be 
presented at academic conferences, published in peer-
reviewed journals and are expected in 2020. A written lay 
summary will be available to study participants on request.
trial registration number NCT02704897; Pre-results.
IntroduCtIon
Surgical site infection (SSI) complicates 
2%–10% of general surgical cases, with the 
highest rates of infection seen after colorectal 
surgery.1 Infection and re-admission rates have 
not significantly changed in the last 10 years. 
The most common causative group is Entero-
bactericae (25% of cases), with Staphylococcus 
aureus (10%) and Methicillin-resistant Staphy-
lococcus aureus (MRSA) (3%) accounting for 
a small proportion of overall cases.1 National 
surveillance data from Scotland indicate 
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Figure 1 Schema of trial events for intervention and control arms.
that peak incidence of infection is between day 6 and 12 
postoperatively.2
A recent study indicated that national reports may 
underestimate the true incidence of SSI, and suggested 
that patient reported SSI is a more sensitive measure.3 
Many patients will have already consulted their general 
practitioner (GP) or attended the emergency depart-
ment (ED) prior to surgical assessment. In addition, 
many patients have concerns about their wounds (in 
the absence of infection) and may experience delays 
in accessing appropriate medical assessment. Thus, SSI 
represents a significant burden on healthcare services, in 
a patient group who are predominantly appropriate for 
outpatient management.
There is currently an increased research focus on 
digital health: the use of communications technology to 
enhance healthcare, public health and delivery of health 
education.4 There are several advantages to this approach, 
in particular the potential to improve access to care, and 
help streamline usage of emergency services. Indeed, 
there is evidence that these technologies have been used 
to improve outcome,5 as well as to reduce specialist work-
load6 and ED attendances.7 In addition, the increasing 
use of healthcare technology is likely to help improve 
automatic data collection and recording, which may be 
used to identify areas for future research and drive quality 
improvement.4
Over three-quarters (78%) of UK adults now own smart-
phones,8 with at least a third using a smartphone as their 
primary device to access the Internet.4 Therefore, there is 
vast potential for the use of smartphones in digital health, 
with a growing literature on the use in the context of post-
operative community follow-up.9 10 Given the frequency 
with which patients report postoperative wound compli-
cations and the high incidence of SSI, this has become a 
research focus in telemedicine for postoperative care.11 12 
We aim to investigate if an online wound assessment tool 
can be used to help diagnose SSI and improve patient 
access to care and clinical assessment. In addition, we 
aim to investigate if this results in earlier intervention to 
treat SSI and a decreased attendance at ED and GPs. The 
widespread use of smartphones, the integrated nature of 
their technology and their portability mean smartphones 
represent the best platform to deliver this tool, with the 
aim of facilitating rapid access to clinical care.
objectives
This randomised controlled trial (RCT) will investigate 
whether a smartphone-delivered wound assessment tool 
can be used in the diagnosis of SSI and result in earlier 
treatment. It will also assess for a reduction in ED and 
GP attendances as a result of using the intervention. Data 
on patient experience will be used to evaluate perceived 
utility of the tool.
MEthodS And AnAlySIS
overview
This is a superiority RCT, using a parallel two-arm design 
(figure 1). Once consent is obtained, participants will 
be randomised in a 1:1 ratio to either the intervention 
arm (receiving standard postoperative care plus access 
to the smartphone-delivered wound assessment tool), or 
the control arm (standard postoperative care). Patients 
will be recruited from the emergency surgery inpatient 
service across National Health Service (NHS) Lothian. 
The trial period will be 30 days. An internal pilot study in 
the first 80 patients recruited will be conducted to ensure 
the trial design is practical and deliverable. Following 
assessment of pilot data, there will an opportunity to adapt 
the trial design in response to the pilot study findings. 
Participants will be followed up by a researcher blinded 
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to the intervention status. The primary outcome measure 
will be the number of days from surgery to diagnosis of 
SSI (time-to-diagnosis), with ED and GP service use as a 
secondary outcome measure. Additional data regarding 
patient experience will also be collected from patients in 
both arms of the trial via a smartphone-delivered ques-
tionnaire at 30 days.
research setting
This research is being carried out in a large health board, 
serving a mixed urban and rural population of over 800 
000. The emergency surgery service admits 300 patients 
per week between participating sites and performs 2500 
procedures annually.
Participants
Emergency surgery inpatients who are adults (over age 
16) and have undergone abdominal surgery (on the 
same admission as diagnosis) will be screened for eligi-
bility. Potentially eligible patients will be screened and 
documented as (a) eligible and included, (b) eligible and 
missed, (c) eligible and declined, (iv) ineligible (visual 
impairment), (v) ineligible (no smartphone). Written 
consent will be obtained by the research team in line with 
good clinical practice guidance. Participation is voluntary 
and a patient’s decision regarding participation will not 
affect any aspect of their care in the case of refusal. Partic-
ipants will have the right to withdraw from the study at 
any point.
Inclusion criteria
Patients admitted to the emergency surgery inpatient 
service who meet the following criteria will be included 
in the study:
 ► Emergency surgery inpatients who have undergone 
abdominal surgery.
 ► Owners of a smartphone, with access to Internet.
 ► Adults over the age of 16.
 ► Able to give informed consent.
Exclusion criteria
Any patients with significant visual impairment preventing 
use of the online questionnaire will be excluded from the 
study (defined by self-reporting of the patient).
Study procedures
Recruitment
The clinical team will inform potentially eligible patients 
about the on-going trial, and offer them further infor-
mation (written and verbal from the research team). 
Eligible patients will be recruited postoperatively as inpa-
tients, with formal written consent taken by a member 
of the research team. Baseline information gathered 
will include: reason for admission, index procedure and 
date, significant co-morbidities—including history of 
diabetes or immunosuppression, as well as age and Body 
mass index (BMI). Participant contact details (mobile 
telephone number) will be entered into a secure, online 
data collection tool (Research Electronic Data Capture 
(REDCap) database).13
Randomisation and blinding
Participants will be assigned in a 1:1 ratio to the inter-
vention or control arms and provided with the appro-
priate information packs prior to discharge. Simple 
randomisation will be carried out using REDCap,13 util-
ising a computer-generated random number sequence. 
The emergency surgery nurses (who will provide care to 
patients as required during the trial) and those taking 
consent (which may include medical students and quali-
fied clinicians) will not be blinded. The clinicians under-
taking follow-up will be blinded to status. A trial entry will 
be made in the clinical notes, including contact details 
for the trial team should a member of the clinical team 
require more information or wish to discover their trial 
status.
Intervention
Smartphone-delivered wound assessment tool
A wound-based instrument to detect potential wound 
infection was developed. Our smartphone-delivered 
wound assessment model was based on the Center for 
Disease Control and Prevention (CDC) classification 
criteria, and the ASEPSIS model (Additional treatment, 
Serous discharge, Erythema, Purulent exudate, and Sepa-
ration of the deep tissues, the Isolation of bacteria, and 
the duration of Inpatient Stay).14 15 It detects symptoms 
of SSI and symptoms of systemic illness as a result of this, 
while being quick and simple to use (table 1).
Participants will have access to the smartphone-deliv-
ered wound assessment tool on discharge via a link sent 
by short-messaging system (SMS) to their smartphones. 
If at any time they have concerns about their wound, 
they can access the tool, and will be advised based on 
their responses. When a patient response is submitted, 
the research team will be automatically notified, and 
prompted to reply (figure 2).
In addition, a link to the smartphone-delivered wound 
assessment tool will be sent on days 3, 7, and 15 postop-
eratively. These time points have been selected to include 
peak incidence of infection and cover the time course of 
wound healing. This will ensure the collection of negative 
data in those without symptoms and will therefore assist 
in determining the specificity of the tool. If participants 
do not respond they will be sent a single reminder at 
these time points.
Wound photographs
Participants will be asked to upload at least one photo-
graph of their wound each time they use the smart-
phone-delivered wound assessment tool. These will be 
reviewed by a clinical researcher and assigned into one 
of three categories: no concerns, medium-risk, high-risk. 
Further machine learning-based assessment of wound 
photographs will be investigated.
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Table 1 Questions included in smartphone-delivered questionnaire and independent algorithm scoring system
Smartphone-delivered wound assessment Algorithm scoring system
Question Response (score) Low-risk Medium-risk High-risk
Is the pain worse than immediately 
after the operation?
No (0), yes (1) Inflammation
score 0
Inflammation
score ≤2
Inflammation
score ≥3
Is there new redness around your 
wound site excluding the wound 
itself?
No (0), yes (1)
Is there more swelling around your 
wound site than at the time of 
surgery?
No (0), yes (1)
Are you experiencing a new burning 
sensation or heat at the wound site?
No (0), yes (1)
AND AND OR
Is there liquid coming from the 
wound site? If so, please select 
which option best describes the 
liquid.
No (0), Discharge
score 0
Discharge
score ≤1
Discharge
score 2Yes—clear (1),
Yes—bloody (1),
Yes—yellowish (1),
Yes—thick/yellow 
(2),
Yes—green/brown 
(2)
Is your wound opening or gaping? No, yes Not scored in algorithm
Have you experienced fevers in the 
last 24 hours?
No, yes
Please upload a photograph of your 
wound.
Photograph Not scored in algorithm
Figure 2 Handling of wound questionnaire submissions.
Responses
An experienced clinician (surgical registrar or consul-
tant) will review all participant responses and photo-
graphs in real time. Based on the response and the 
wound photographs, they will contact the patient by SMS 
with advice regarding the need for further assessment. 
The clinician will classify participants into three groups: 
no concern, medium-risk, high-risk. These three groups 
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were agreed collectively by the researchers in collabora-
tion with the emergency surgical team. Three potential 
outcomes were identified: (i) the patient does not require 
further assessment (no concern), (ii) the patient requires 
further assessment, but the symptoms identified suggest a 
mild infection (medium-risk), (iii) the symptoms suggest 
a potentially severe infection requiring urgent assessment 
(high-risk). The wound photographs will also be reviewed 
by the experienced clinician where available and classi-
fied into the same three groups. This may be used by the 
researcher to refine their response to the tool, if they 
consider this necessary.
Algorithm
An algorithm has been designed to classify participant 
responses into the same three categories listed earlier 
(table 1). This will be run on all participant responses 
(but will not impact on care), and will be compared with 
clinician rating, as a secondary sub-study. The correla-
tion between clinician response, algorithm response and 
photo response will be used to determine if the algorithm 
can be used to assess for SSI independent of the respon-
sible doctor.
Action from response
Participants whose responses raise no concerns will be 
advised of this. Participants who report symptoms consis-
tent with wound infection will be directed for further 
assessment. Those in the medium-risk group will be 
directed to community care while those in the high-risk 
group will be advised to return for assessment at the 
centre where they had their procedure. This advice aligns 
to the degree of concern identified previously.
Wound reviews
For those in the intervention group who are identified 
as high-risk, the emergency surgery nurses will collect a 
wound swab from the patient to test for causative organ-
isms (and aid in confirming infection). If a wound infec-
tion is diagnosed clinically, the patient will be started 
with antibiotics in line with local guidelines. This will be 
logged in the patient’s trial record. If any patients in the 
control group attend the emergency surgery service for a 
review the same procedures will apply.
GPs will be informed about their patient’s participation 
in the trial. We will request that if a participant enrolled 
in the trial visits their GP a wound swab is taken, and that 
they are treated in line with the GP’s normal practice. 
This will also apply to those in the medium-risk group 
who will be directed to their GP.
All participants will be given a log to take to any 
wound reviews, and wound swabs may be taken of wound 
discharge or the wound bed as appropriate. If an infec-
tion is diagnosed the date treatment is commenced will 
be noted, alongside any intervention performed. This 
will then be returned to the trial team, and used in 
follow-up.
30-day follow-up
Both arms will receive a follow-up face-to-face or tele-
phone consultation 30 days postoperatively (alternatively, 
written follow-up is also available for those with signifi-
cant hearing impairment). This consultation will follow a 
standardised format and will be conducted with an inde-
pendent clinical researcher blinded to the intervention 
status. The clinical researcher will gather data on post-
operative course, any symptoms related to the wound 
and any treatment offered. They will also have access 
to electronic patient record (including all microbiology 
results from swabs taken in the community or hospital) 
and any wound logs returned. On the basis of these three 
sources of information, two independent, blinded clinical 
researchers will determine if an infection has been present 
(trained using the CDC criteria to diagnose infection).14 
Data on patient experience and service usage—ED and 
GP attendances, as well as contact with emergency surgery 
nurses—will also be collected via a separate questionnaire 
delivered alongside the 30-day follow-up (table 2).
data analysis plan
All analysis will be carried out on an intention-to-treat 
basis. We do not anticipate missing data in patient 
demographics. However, any missing data values will 
be handled using multiple imputation. The volume of 
missing outcome data will be recorded for the control 
and intervention arms, and any differences in drop-out 
rate noted. Thereafter patients with missing outcome 
data will be excluded from analysis.
Outcome measures
This is a superiority RCT, and the primary outcome will 
be mean time from operation to diagnosis (time-to-diag-
nosis) of SSI. This outcome has been chosen (rather than 
time from symptom onset), as it can be more accurately 
recorded and is a measure of improved access to care. 
We assume an equal incidence of SSI in both groups and 
will ensure this using ORs. Time-to-diagnosis will also 
be compared using Cox proportional hazard regression 
analysis; a p value of<0.05 will be considered statistically 
significant.
For the intervention, we will calculate the sensitivity 
and specificity of the researcher response, the algorithm 
response and photograph response in the diagnosis of 
SSI. We will compare the correlation of the algorithm, 
which is based on questionnaire responses, with clinician 
advice and eventual diagnosis. Correlation analysis will be 
performed using Kendall tau rank test. This will assess the 
accuracy of the algorithm in stratifying risk, as compared 
with a clinician, and will indicate what additional benefit 
may be gained from photographic analysis.
The secondary outcome measure will be use of services: 
GP and ED attendances, as well as contact with emer-
gency surgery nurses. This data will be gathered at 30 days. 
Differences in number of attendees to GP and ED will be 
compared using a χ2 test. Differences in the number of 
attendances will be assessed using the Mann-Whitney U test.
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Table 2 Questions included in smartphone-delivered 30-day patient experience questionnaire
Smartphone-delivered 30-day patient experience questionnaire
Question Available responses
1. Did you have access to the smartphone tool? Yes, no
2. If you had access to the tool, how many times did you use 
the tool (not including the reminder questions sent)?
(integer)
3. If you had access to the tool, please rate the extent to 
which you agree/disagree with the statements below:
a. The tool was easy to use Strongly disagree, disagree, neutral/no opinion, agree, strongly 
agree.
b. I understood the questions in the tool Strongly disagree, disagree, neutral/no opinion, agree,strongly 
agree.
c. It was easy to upload my wound photo Strongly disagree, disagree, neutral/no opinion, agree,strongly 
agree.
d. The response from the tool was helpful Strongly disagree, disagree, neutral/no opinion, agree,strongly 
agree.
4. Please rate the extent to which you agree/disagree with the 
statements below:
a. It was easy to get hold of advice about my wound when 
needed
Strongly disagree, disagree, neutral/no opinion, agree, strongly 
agree.
b. I had to wait more than 1 day for advice about my wound Strongly disagree, disagree, neutral/no opinion, agree,strongly 
agree.
c. The advice I received about my wound was useful Strongly disagree, disagree, neutral/no opinion, agree,strongly 
agree.
Data on patient experience will also be gathered via a 
follow-up questionnaire and analysed separately (table 2). 
This will help determine if an online questionnaire deliv-
ered via a smartphone has a positive impact on patient 
experience of care, and if it helped facilitate their access 
to care.
Sample size and power analysis
Our primary outcome measure is time-to-diagnosis and 
we aim to detect a 1 day difference with a power of 90% 
(alpha 0.05). Assuming a SD of 1 day in time-to-diag-
nosis, 22 wound infections per group will be required. 
Estimating a 10% rate of wound infection (in line with 
national data)2 and a drop-out rate of 10%, a sample size 
of 490 will be required (recruitment target 500 patients). 
Analyses will be intention-to-treat.
Assuming that 50 operations are performed per week and 
two thirds of these patients are likely to own smartphones, 
we estimate there will be 30 potentially eligible patients per 
week. Aiming for recruitment of 25% of eligible patients, 
we estimate a continuous recruitment time of 16 months. 
This rate of recruitment will also enable the researcher to 
respond to all patient concerns in a timely manner.
EthICS And dISSEMInAtIon
Safety
All participants will receive the normal standard of care. 
The smartphone-based intervention is in addition to the 
normal standard of care. If at any point participants have 
any concerns. they will be advised to contact the emergency 
surgery nurses regarding their care (in line with normal 
standard of care). Out-of-hours they will be advised to 
contact NHS out-of-hours services. Participants will be 
advised to contact the emergency surgery nurses if they 
have any concerns while they are awaiting a response to the 
tool. The research team will be notified automatically that a 
participant is awaiting a response, ensuring that in normal 
working hours patients receive a rapid reply. They will also 
be advised that if they access the tool at night, that it will not 
be reviewed until the following day. They will be advised 
to contact out-of-hours services if they require an overnight 
assessment. These actions will prevent any harm to patients 
resulting from a delayed response to the wound assessment 
tool. A potential consequence of closer follow-up of these 
postoperative patients could be increased identification of 
superficial SSI which would likely otherwise self-resolve; 
however, this would require closer surveillance or treat-
ment if appropriate (this decision is made by an indepen-
dent clinician at the time of review). Due to the low-risk 
nature of the trial, a formal data-monitoring committee has 
not been nominated.
data protection and management
All participant data will be stored securely in a REDCap13 
database that has controlled access and designed as 
compliant with Health Insurance Portability and Account-
ability (HIPAA) security guidelines. This data will be 
anonymised, and only available to researchers listed on 
the protocol. Participant responses to the questionnaire 
will be reported directly to the REDCap database and will 
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not be stored on patient phones. However, patients will 
be advised to review the security setting on their phone 
if they intend to store their wound photographs. Patient 
details will be recorded in a trial log should any safety 
concerns arise necessitating they be contacted.
Ethical approval and dissemination plan
Any protocol amendments will be resubmitted for review. 
The study is sponsored by ACCORD, a collaboration 
between the University of Edinburgh and NHS Lothian 
Research and Development. In line with good clinical 
practice guidance, written consent will be obtained by 
appropriately trained medical students or clinicians. 
Participation is voluntary and a patient’s decision 
regarding participation will not affect any aspect of their 
care in the case of refusal. Participants will have the right 
to withdraw from the study at any point.
Authorship on any papers derived from the study will 
be all authors involved in study design and protocol 
development, and any additional researchers involved 
in the writing group. Furthermore, patient recruiters 
who have recruited more than the prespecified 15 
patients to the study will be listed as a ‘collaborator’. All 
other persons involved in the study will be listed in the 
acknowledgements.
There are no financial and other competing interests 
for principal investigators for the overall trial or either 
study site. Study findings will be reported in line with 
Consolidated Standards of Reporting Trials (CONSORT) 
guidelines, and disseminated in the printed media, and 
learnt forums, and are expected by 2020. A written lay 
summary will be available to study participants on request.
Patient and public involvement
Patients were not directly involved in the design or 
delivery of this trial; however data on patient experi-
ence in using the smartphone tool will be evaluated via a 
follow-up questionnaire. This will inform future develop-
ment and dissemination of this intervention. A summary 
of results will be provided to all patients involved once the 
trial has been completed and analysed.
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